Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Advertisements

DelveInsight’s, “Marginal Zone Lymphoma Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including Marginal Zone Lymphoma clinical trials and nonclinical stage products. It also covers the Marginal Zone Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Marginal Zone Lymphoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Marginal Zone Lymphoma NDA approvals (if any), and product development activities comprising the technology, Marginal Zone Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from Marginal Zone Lymphoma Pipeline Insight Report

DelveInsight’s marginal zone lymphoma pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for marginal zone lymphoma treatment. 
Key marginal zone lymphoma companies such as Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, and others are evaluating novel marginal zone lymphoma drugs candidate to improve the treatment landscape.
Promising marginal zone lymphoma pipeline therapies in various stages of development include Tafasitamab, Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, GDA-201, BGB-16673,  LOXO-305, and others.

 

To explore more information on the latest breakthroughs in the Marginal Zone Lymphoma Pipeline treatment landscape of the report, click here @ Marginal Zone Lymphoma Pipeline Outlook

 

Marginal Zone Lymphoma Overview

Marginal zone lymphoma (MZL) is the second most common indolent non-Hodgkin’s lymphoma (iNHL). There are three types of marginal zone lymphomas: the extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT or gastric GALT), the splenic MZL, and the nodal MZL. EMZL can originate at virtually any extranodal site and arises in organs that normally lack lymphoid tissue (eg, stomach, intestine, thyroid, lung, and skin). The most frequently affected organ in EMZL is the stomach, and there is compelling evidence for a causal relationship between H. pylori and gastric EMZL. SMZL arises predominantly from the marginal zone memory B-cells located in the follicles of the spleen, splenic hilar lymph nodes, BM, and the peripheral blood. The pathogenesis of SMZL has yet to be fully understood; similar to other subtypes of MZL, it likely involves the persistent stimulation of BCR signaling pathway, with increasing proliferation and survival of malignant B cells. NMZL is the least common subtype of MZL.

 

Recent Breakthroughs of Marginal Zone Lymphoma Treatment Landscape

In August 2022, Gamida Cell announced dosing of the first patient in a company-sponsored Phase I/II study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular, diffuse large B cell lymphomas and marginal zone lymphoma or mantle cell lymphoma.
In August 2022, Orelabrutinib’s supplemental New Drug Application (sNDA) was accepted by the China National Medical Products Administration (NMPA) for the treatment of patients with relapsed or refractory Marginal Zone Lymphoma (R/R MZL).
In June 2022, ADC Therapeutics announced the first patient has been dosed in LOTIS-7, a Phase 1b clinical trial evaluating ZYNLONTA in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The first arm of the LOTIS-7 open-label, multi-center, multi-arm Phase Ib trial will evaluate the safety and activity of ZYNLONTA in combination with polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Burkitt lymphoma.
In May 2022, Oncternal Therapeutics announced that the CIRLL clinical trial (CIRM-0001) is a Phase I/II trial evaluating zilovertamab in combination with ibrutinib in separate groups of patients with CLL or MCL. Enrollment of the dose-finding cohorts in CLL and MCL, dose-expansion cohort in CLL and MCL and randomized Phase II cohort in CLL has been completed. An additional dose-expansion cohort of up to 10 patients with marginal zone lymphoma (MZL) has recently been added. Enrollment is expected to begin in Q2 2022.

 

Request a sample and discover the recent advances in Marginal Zone Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Marginal Zone Lymphoma Treatment Landscape

 

Marginal Zone Lymphoma Emerging Drugs

Tafasitamab: Incyte Corporation

Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma. 

 

Amdizalisib (HMPL-689): HUTCHMED

The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3’-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib’s pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin’s lymphoma, including follicular lymphoma and marginal zone lymphoma.

 

Orelabrutinib: InnoCare Pharma

Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).

 

EO2463: Enterome

EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.

 

Marginal Zone Lymphoma Pipeline Therapeutic Assessment

There are approx. 50+ key companies which are developing the therapies for Marginal Zone Lymphoma. The companies which have their Marginal Zone Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Incyte Corporation.

 

DelveInsight’s Marginal Zone Lymphoma Pipeline report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

  

Scope of the Marginal Zone Lymphoma Pipeline Report

Coverage- Global
Marginal Zone Lymphoma Pipeline Assessment: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Marginal Zone Lymphoma Companies- Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, VelosBio Inc., Newave Pharmaceutical Inc, Boryung Pharmaceutical Co., Ltd, Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc., Gamida Cell, BeiGene, Loxo Oncology, and others
Marginal Zone Lymphoma Therapies- Tafasitamab, Orelabrutinib, EO2463, MIL62, Loncastuximab, NX-2127, LP-168, Zandelisib, BR101801, BP1002, Mosunetuzumab, CLR 131, IBI376, Pirtobrutinib, Zilovertamab vedotin, TG-1801, VAY736, ADI-001, CDX-1140, PSB202, Acalabrutinib, axicabtagene ciloleucel, Obinutuzumab, Cirmtuzumab, Nemtabrutinib, Lenalidomide, IGM-2323, Epcoritamab, GDA-201, BGB-16673,  LOXO-305, and others.

 

Table of Content

Introduction
Marginal Zone Lymphoma Executive Summary
Marginal Zone Lymphoma Overview
Marginal Zone Lymphoma Pipeline Therapeutics
Marginal Zone Lymphoma Pipeline Therapeutic Assessment
Marginal Zone Lymphoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Tafasitamab: Incyte Corporation
Mid Stage Products (Phase II)
Orelabrutinib: InnoCare Pharma
Early Stage Products (Phase I/II)
EO2463: Enterome
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
Marginal Zone Lymphoma Key Companies
Marginal Zone Lymphoma Key Products
Marginal Zone Lymphoma- Unmet Needs
Marginal Zone Lymphoma- Market Drivers and Barriers
Marginal Zone Lymphoma- Future Perspectives and Conclusion
Marginal Zone Lymphoma Analyst Views
Marginal Zone Lymphoma Key Companies
Appendix

 

Got Queries? Find out the related information on Marginal Zone Lymphoma Mergers and acquisitions, Marginal Zone Lymphoma Licensing Activities @ Marginal Zone Lymphoma Emerging Drugs, and Recent Trends

 

Related Reports- Stem Cell Market | Asperger Syndrome Market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.

Advertisements

Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: